The impact of National Comprehensive Cancer Network (NCCN) treatment guideline concordance on costs, health care utilization, and mortality for patients with breast cancer and secondary metastases is unknown. METHODS: From 2007 to 2013, women with early-stage breast cancer who received treatment for secondary metastases (n = 5651) were evaluated for first recorded systemic therapy concordance with NCCN guidelines within the Surveillance, Epidemiology, and End Results Program-Medicare linked database. Generalized linear and mixed effects models evaluated factors associated with nonconcordance and the relation between concordance status and health care utilization and costs. Mortality risk was estimated with Cox regression. RESULTS: Eighteen percent of the patients received nonconcordant therapy, with the most common being single-agent, human epidermal growth factor receptor 2 (HER2)-targeted therapy (36%), therapy mismatched with the estrogen receptor/HER2 status (11%), unapproved bevacizumab regimens (10%), and adjuvant regimens in a metastatic setting (6%). A younger age, a hormone receptor-negative status, and a HER2-positive status were associated with nonconcordance (P < .05). Nonconcordance was associated with 22% and 21% increased rates of emergency department visits and hospitalizations, respectively, and $1765 higher average monthly Medicare costs. Differences in adjusted mortality risk were noted by the category of nonconcordance; single-agent, HER2-targeted therapy was associated with decreased mortality risk (hazard ratio [HR], 0.66; 95% confidence limit [CL], 0.57-0.76), and increased mortality risk was observed with unapproved bevacizumab use (HR, 1.40; 95% CL, 1.13-1.74). CONCLUSIONS: Most patients (82%) received treatment consistent with NCCN guidelines. Nonconcordant treatment was associated with higher health care utilization and costs, with mortality differences observed by the type of guideline deviation. Consideration of both patient and financial outcomes will be important as health systems increase the emphasis on guideline-based care. Cancer 2018;124:4231-4240.
INTRODUCTION
For more than 20 years, the National Comprehensive Cancer Network (NCCN) treatment guidelines have guided the treatment of breast cancer. 1 The receipt of treatment according to guidelines is increasingly being recognized as a marker of high-quality care. [2] [3] [4] However, 11% of patients receive chemotherapy agents not listed within guidelines, with stage III/IV patients more likely to receive nonconcordant treatment than patients with early-stage diease. 5 Previous literature considered whether specific medications, rather than chemotherapy combinations, were listed in NCCN guidelines. 5 A knowledge gap remains regarding concordance for regimens, which include specific single agents or combinations of hormone therapy, chemotherapy, and targeted therapies. In addition, the NCCN has identified preferred treatment regimens to narrow recommendations, 6 but no data exist on how often these regimens are selected. Nonconcordant treatments contribute to the rising cost of cancer care. 7 In 2010, 10 chemotherapy agents inconsistent with NCCN guidelines contributed an estimated $2.5 billion to US cancer spending. 8 To control costs, several payers are implementing pathway programs restricting reimbursement for non-guideline-based care. 3, [9] [10] [11] However, the relation between guideline concordance and patient outcomes is not fully established, particularly in the setting of metastatic breast cancer (MBC), for which treatment is heterogeneous and complex because of the large number of available guideline-based options. To ensure optimal patient care, it is essential to understand the commonly prescribed nonconcordant treatments, patient-and provider-level factors associated with concordance, and the impact of nonconcordance on patient outcomes. The study objectives were to determine the rates of concordance of treatment regimens received with NCCN guidelines for breast cancer patients with secondary metastases; to understand categories of nonconcordant treatments; to assess patient-and provider-level factors associated with nonconcordance; and to evaluate the impact of nonconcordance on health care utilization, health care spending, and mortality.
MATERIALS AND METHODS

Data Sources
Data were obtained from the Surveillance, Epidemiology, and End Results Program (SEER)-Medicare linked database from 2000 to 2013. 12 
Patient Population
Patients with American Joint Committee on Cancer stage I to III breast cancer diagnosed between 2000 and 2013 were identified. 13 We included women with primary, early-stage breast cancer who developed secondary, distant metastases between 2007 and 2013 and who also received treatment after the presence of metastases with chemotherapy, hormone therapy, or targeted therapy (Fig. 1 14, 15 The first claim date with ICD-9 codes for secondary cancer was considered the index date. Exclusion criteria included making claims after patient health maintenance organization enrollment, not having Medicare Parts A, B, and D from diagnosis through the first recorded treatment, being male, having multiple cancers, and having likely billing errors identified by the receipt of agents within the same class on 1 day.
Characterizing Treatment Regimens
We identified the first recorded hormonal, chemotherapy, and human epidermal growth factor receptor 2 (HER2)-targeted therapy regimen (either single or combination) after the index date with National Drug Codes, the Healthcare Common Procedure Coding System, and generic drug names. Treatments were considered combinations if drug claims were billed on the same day. Nonconcordant treatments were reviewed and grouped into nonoverlapping categories.
Concordance With NCCN Guidelines
Concordance was defined as a match between the treatments received and the regimens listed in the version of the NCCN guidelines published at the time of treatment. Chemotherapy concordance was defined separately for HER2+/-breast cancers. Patients with an unknown HER2 status were considered concordant if they received a HER2+ or HER2-regimen. Concordant regimens were categorized into subgroups on the basis of being listed as preferred or other regimens within NCCN guidelines.
Patient Characteristics
Patient characteristics included the following: age at the first recorded metastatic treatment date, race (white vs black vs other), residence (urban vs rural), census-tract poverty level (<20% vs ≥20% of the federal poverty level), reason for Medicare entitlement (age vs disability/ Cancer November 1, 2018
end-stage renal disease), dual eligibility (ever vs never), census-tract education level (mean % non-high school education vs mean % high school education or greater), hormone receptor status (positive vs negative vs unknown), HER2 status (positive vs negative vs unknown), and Charlson comorbidity index score. Comorbid conditions in the year before the development of secondary metastases were abstracted from claims data and were classified with a weighted score of 0, 1, 2 to 3, or 4+ on the basis of the Klabunde modification for comorbidities. [16] [17] [18] Prior chemotherapy was defined within the first year after the patient's stage I to III cancer diagnosis and before the index date.
Prescribing Providers
For patients receiving infused medications, the assigned oncology provider was the prescribing provider (identified by the National Provider Identifier or Unique Physician Identification Number) associated with the claim. For patients receiving oral treatment, when there was not a linked provider, we identified the oncology provider with the closest evaluation and management code on or before the first recorded treatment. If there was no oncology provider with evaluation and management codes before treatment, the closest non-oncology provider was selected. The following provider characteristics were abstracted from the American Medical Association database: sex, years since medical school graduation, medical training location (US vs foreign), and specialty (hematology-oncology vs other).
Each provider was assigned a hospital on the basis of the practice location associated with the most inpatient and outpatient claims for each specific provider. The following additional provider characteristics were identified on the basis of their affiliated hospital: SEER region (Northeast vs South vs Midwest vs West), medical school or National Cancer Institute (NCI) designation (medical school and NCI designation vs medical school with no NCI designation vs neither), rural hospital status (rural primary hospital qualification or rural hospital location or critical access hospital vs none), total number of beds, and cooperative group count.
Costs to Medicare and Health Care Utilization
Costs were calculated from Medicare reimbursements to providers obtained from inpatient (Medicare Provider and Analysis Review), outpatient (Outpatient Standard Analytic File), National Claims History, and Durable Medical Equipment files. Part D costs were excluded.
Average costs per month were calculated on the basis of the number of follow-up months available for each patient. Emergency department visits and hospitalizations were identified from the index date until death or censorship (defined as the last available claim).
Patient Outcomes
All-cause mortality was defined as death from any cause. The length of follow-up was defined as the time from the first recorded treatment until death or censorship.
Statistical Analysis
To assess patient and provider factors, emergency department visits, and hospitalizations associated with nonconcordance, we used generalized log-linear models with the Poisson distribution and log-link function to estimate rate ratios (RRs) and 95% CLs. Patient and provider models accounted for patient clustering within providers. Utilization models were adjusted for the calendar time and the length of patient follow-up. Linear mixed effects models were used to evaluate trends in average monthly costs, with adjustments made for the calendar time. A 5% false discovery rate was used to correct for the number of tests performed to determine the association between cost or utilization and nonconcordant treatment. Cox proportional hazards models were used to compare all-cause mortality by concordance status. All hazard models were adjusted for the hormone receptor/HER2 status, Charlson comorbidity index score, age at metastatic disease, race, and census-tract poverty. Models were assessed for the proportionality of the hazards assumption with the Kolmogorov-Smirnov test, and time-dependent covariates were added for the Charlson comorbidity index score and age at metastatic disease. Sensitivity analyses for concordance status were performed by the presence of a known receptor status versus an unknown receptor status. All analyses were performed with SAS software (version 9.4; SAS Institute, Inc, Cary, North Carolina). This study was approved by the institutional review board at the University of Alabama at Birmingham.
RESULTS
Patient Population
The study included 5651 patients (Fig. 1) . The population was predominantly older, white females ( Table 1) . The median overall length of follow-up after the first recorded metastatic treatment date was 1.3 years (95% CL, 0.9-1.8 years).
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Concordance With NCCN Guidelines
The first recorded treatment for MBC was concordant with NCCN guidelines for 82% of the patients (Table 1) . Of those receiving concordant treatment, 97% received preferred regimens, and 3% received other regimens. Sensitivity analyses excluding unknown receptor statuses showed no difference in concordance status.
Categories of Nonconcordance
For patients receiving nonconcordant treatment (n = 1027), discrete categories emerged, including 1) HER2-targeted therapy without chemotherapy, 2) adjuvant regimens used in the metastatic setting, 3) therapy mismatched with the estrogen receptor/HER2 status, 4) unapproved bevacizumab regimens, and 5) other miscellaneous reasons. Use of HER2-targeted therapy without chemotherapy (36%) was the most common nonconcordant treatment category (Fig. 2) . Nonconcordant adjuvant regimens included docetaxel and cyclophosphamide; doxorubicin and cyclophosphamide; and docetaxel, doxorubicin, and cyclophosphamide. Bevacizumab was used in 39 nonconcordant combinations.
Factors Associated With Nonconcordance
A younger age, a hormone receptor-negative status, and a HER2-positive status were associated with nonconcordant treatment. Provider characteristics, including years from training (RR, 1.00; 95% CL, 0.99-1.00), hematology-oncology specialty (RR, 1.13; 95% CL, 0.93-1.38), and rural hospital status (RR, 0.96; 95% CL, 0.76-1.22), were not associated with nonconcordant treatment (Supporting Table ) .
Costs to Medicare and Health Care Utilization
In comparison with concordant treatments, nonconcordant treatments were associated with $1765 higher average Medicare costs per month (95% CL, $1237-$2294; Table 2 ). The median follow-up time was 16 months. Table 2 ). No differences in rates of utilization were seen between categories of nonconcordance. Conclusions were similar after a false discovery rate adjustment at the 5% level.
Mortality Risk
During the follow-up period, 61.8% of the patients died.
Patients receiving concordant and nonconcordant treatments had similar adjusted mortality risks (hazard ratio [HR], 0.93; 95% CL, 0.85-1.02; Fig. 3 ). However, substantial differences were noted by the category of nonconcordance (Table 3 and Fig. 4 
DISCUSSION
This analysis is the first comprehensive assessment of the impact of guideline-based treatment regimens for patients with early-stage breast cancer who develop secondary metastases. Although the majority of patients received concordant treatment, almost 1 in 5 women did not. In contrast to early-stage breast cancer, for which guideline-based care is associated with improved survival, [19] [20] [21] we found no survival difference between patients with MBC receiving concordant treatment and patients with MBC receiving nonconcordant treatment. This lack of a difference may be due to the heterogeneity of care and differing treatments in later lines, which may minimize differences in outcomes related to the first recorded therapy.
Nonconcordant category grouping may also contribute to the lack of a survival difference. The most common type of nonconcordant treatment was the use of HER2-targeted therapies (trastuzumab and lapatinib) b Guideline-discordant versus guideline-concordant. The model was adjusted for the calendar time and the length of patient follow-up.
Cancer November 1, 2018 without chemotherapy, which was associated with improved mortality but higher costs. Given the strong benefits of HER2-targeted therapy, 22 oncologists may consider these single agents to be valuable for frail, older patients who are unlikely to tolerate cytotoxic chemotherapy. The alternative guideline-based option would be to forgo HER2-targeted therapy and use endocrine therapy alone. The approach of single-agent, HER2-targeted therapy has since been tested within the EMILIA trial, which demonstrated superior overall survival with trastuzumab emtansine, which combines a cytotoxic agent with trastuzumab, in comparison with capecitabine and lapatinib. 23 Further research is needed to evaluate single-agent, HER2-targeted therapy in frail, older populations.
Although bevacizumab is rarely used in the United States today, these data provide a cautionary tale. Although phase 2 studies of bevacizumab with agents other than paclitaxel were published during the study period, [24] [25] [26] the only combination listed within NCCN guidelines was bevacizumab and paclitaxel. These real-world data demonstrate the use of bevacizumab in 39 non-guideline-based combinations with increased cost, hospitalizations, and mortality risk. This widespread use may have been a result of promising preliminary data 27 Cancer November 1, 2018 and provider belief that bevacizumab would be beneficial. Use of bevacizumab has been reported as a large driver of costs related to nonconcordant treatment. 8 The ultimate removal of Food and Drug Administration approval in 2010 28 highlights the need for clinicians to wait for definitive evidence of a benefit rather than extrapolating early positive results to untested regimens as new agents are brought to market.
This study demonstrated both lower health care utilization and lower Medicare costs for patients receiving guideline-concordant care. These findings are influenced by patients receiving single-agent hormone therapy, which is less costly, less toxic, and categorized as concordant. This underscores the importance of considering hormonal therapy for patients with hormone-responsive disease, including patients with visceral metastases. 6, 29, 30 In this analysis, patient factors (a younger age, a hormone receptor-negative status, and a HER2-positive status) were associated with guideline concordance. These differences may be secondary to higher chemotherapy use in this population, whereas older, hormone receptor-positive, HER2-negative patients are likely to receive guideline-concordant endocrine therapy. In contrast, provider factors were not associated with guideline concordance. This contrasts with a study in early-stage breast cancer by Denu et al, 21 who found lower concordance for physicians who were more than 15 years from medical school graduation and were practicing at smaller hospitals. However, this study was based on a small sample (n = 107), which contrasts with our large (n = 5651), nationwide sample. However, other provider factors, such as a belief in the importance of guideline-based care and training in evidence-based medicine, may contribute to the likelihood of concordant care, which is uncaptured by the American Medical Association.
As practice patterns come under intensive scrutiny, we must consider the purpose of guidelines, which are created to help clinicians to make up-to-date, evidence-based treatment decisions. NCCN treatment guidelines include more than 40 different treatment choices for MBC, including single agents and combinations. 6 The inclusive nature of the NCCN guidelines may represent a fear of limiting physician choice, particularly in an era when insurance agencies are increasingly looking to guidelines for appropriate treatment justification. 31 The tension between including all options should be weighed against the danger of not providing enough guidance for practicing physicians. The preferred category can aid in narrowing options. Our analysis demonstrates that 3% of the patients received guideline-concordant care that was not preferred, and this suggests an opportunity to refine the guidelines for more meaningful recommendations. At the same time, our analysis highlights concerns regarding limited formularies. Single-agent, HER2-targeted therapy was associated with improved survival, and this emphasizes the appropriateness of off-guideline care for specific patients according to their preferences and comorbidities. Guideline concordance should rarely, if ever, be 100%. 11 Understanding practice variability, including when deviations may be appropriate, is essential to continued physician autonomy in decision making. Undoubtedly, pathway program utilization will increase over the next decade because of the benefits of improved standardization of care, shorter therapy durations, and reduced hospitalization and costs. 3, 10, 11, 31, 32 However, a better understanding of nonconcordant choices and implications for patient outcomes is needed to inform guideline and pathway development.
This study has several limitations. This analysis does not include all patients with MBC but rather involves a subset with early-stage breast cancer that developed secondary metastases and received treatment. In addition, patients may develop metastatic disease before the first claim documenting a secondary malignancy. Therefore, our first recorded treatment for secondary metastasis may actually be a later line. However, guidelines during this time do not specify treatment by line, so they could be applied to either first or later lines of treatment. This analysis also does not consider all treatment lines; later lines could influence survival outcomes. In addition, clinical trial participation was not captured in this analysis. However, categories of nonconcordance would not be consistent with clinical trials. Another limitation is the lack of the HER2 status in SEER-Medicare data until 2010, although the sensitivity analysis did not show differences in patients with an unknown receptor status. Other unmeasured confounders exist in SEER-Medicare data, such as the patient or physician treatment preference. In addition, unmeasured patient-level characteristics, such as disease burden or visceral crisis, preexisting toxicities or treatment side effects, and other unrelated health conditions may also drive treatment choice and patient outcomes. This study also focuses solely on Medicare patients, who may not be representative of all patients with MBC, including younger patients with commercial insurance. We also acknowledge that patient comorbidities may drive nonconcordant care toward less toxic regimens, and this may explain the high use of single-agent, HER2-targeted therapy (36%).
In conclusion, 18% of patients with MBC received treatment inconsistent with NCCN treatment guidelines, and this suggests an opportunity to increase standardization. Health care utilization and costs were higher for patients receiving nonconcordant treatments. Although mortality was not substantially higher among patients receiving nonconcordant treatments, the mortality risk varied (in both directions) by the category of nonconcordance. These findings may influence policy decisions regarding the implementation of pathway programs as health systems transition to value-based models.
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